Designing a microchip for exosome isolation with the ability to simultaneously impregnate it with imatinib: an in vitro analysis

Amir Monfaredan, Elahe Motevaseli, Gholamreza Tavoosidana
Tehran University of Medical Sciences, Department of Molecular Medicine, School of Advanced Technologies in Medicine, http://en.tums.ac.ir/
Tehran 1416753955, Iran
E-mail: monfaredanamir@gmail.com, e_motevaseli@tums.ac.ir, g-tavoosii@tums.ac.ir

Fakher Rahim
Cihan University-Sulaimaniya, https://sulicihan.edu.krd/
Sulaimaniya 46001, Iraq
E-mail: rahim.fakber@sulicihan.edu.krd

Kudaiberdi G. Kozhobekov
Osh State University, https://oshsu.kg/
Osh 723500, Kyrgyzstan
E-mail: kudayberdi.kozhobekov@oshsu.kg

Mohammad Hossein Modarressi
Tehran University of Medical Sciences, Department of Medical Genetics, Faculty of Medicine, http://en.tums.ac.ir/
Tehran 1416753955, Iran
E-mail: modaresi@sina.tums.ac.ir

Alaviyehsadat Hosseininasab
GeneDia Life science company, https://tracxn.com/
Tehran 13000-15000, Iran
E-mail: sbrzd bsni@gmail.com

Ali-Akbar Aghajani-Afrouzi
Payame Noor University, Department of Business Administration, https://pnu.ac.ir/
Tehran 19569, Iran
E-mail: aghajaniali3@gmail.com

Mahdi Shafiee Sabet
Tehran University of Medical Sciences, School of Medicine, http://en.tums.ac.ir/
Tehran 1416753955, Iran
E-mail: mshafiees@sina.tums.ac.ir

Received January 17, 2024, peer-reviewed January 18, 2024, accepted January 19, 2024, published April 25, 2024

Abstract: Exosomes, a small bilayer membrane derived from eukaryotic cells, have been identified as a useful natural delivery platform due to their suitable size, biocompatibility, structural stability, high loading capacity, and editable surface capability. Due to the difficulty of maintaining the highly pure exosome, several attempts have conducted the techniques for exosome isolation. In recent years, microstructures have found many applications in chemistry, biology, and medicine due to their high accuracy and low cost of materials. Soft lithography is a low-cost, fast, accurate, and yet widely used method of construction of Micron channels. In the present study, a soft lithography process has been performed to construct channels for exosome separation with immunoaffinity function. Both biochemical and biophysical categories tests were performed to examine the quality of extracted exosomes from different sources (serum, cell supernatant, and urine) and compared with the commercially available kit. Results showed that the current technique was capable to isolate exosomes with a high yield rate, purity, and low time consumption. All forms of the imatinib loaded exosomes exhibited the antitumor activity against KYO-1 cell line.
1. INTRODUCTION

Extracellular vehicles (EVs) or exosomes have developed as one of the interest fields due to their noteworthy role in not only biological processes but also, provide biocompatible vehicles for diagnosis and therapy [1]. Exosomes are small size biocompatible vesicles that are able to escape from mononuclear phagocyte system (MPS) [1]. The application of exosomes in biomedical diagnostics and therapy has highlighted the urgent need for new technologies in rapid and accurate methods of exosome separation in body fluids. Due to the biomolecule content of exosomes like proteins, nucleic acids (m. RNAs, microRNAs, and DNA), numerous attempts have conducted with the diagnostic and therapeutic potential of exosomes, related to their role in cell-cell communications and drug delivery, respectively. One of the main challenges is related to overcoming the fluid complexity and the lack of efficient techniques for isolation [2-4]. Exosomes are cell-derived structures packaged with lipids, proteins, and nucleic acids. They are found in various body fluids and play a role in physiological and pathological processes. Although their potential for clinical application as diagnostic and therapeutic tools has emerged, a major bottleneck hindering the development of applications in the rapidly growing field of exosome research is the inability to effectively separate purified exosomes from other undesirable components in body fluids. To date, various approaches for the isolation of exosomes have been proposed and investigated; their main candidate is
microfluidic technology due to its relative simplicity, cost-effectiveness, and ability for precise and rapid microscale processing and automation. In particular, eliminating the need for exosome labeling represents a significant advance in terms of process simplicity, time and cost, as well as in terms of preserving the biological activities of exosomes. Despite the exciting progress in microfluidic strategies for exosome isolation and the numerous advantages of label-free approaches for clinical applications, existing microfluidic platforms for exosome isolation still face a number of issues and challenges that hinder their use for sample processing [5-8]. This review focuses on recently developed microfluidic platforms for label-free isolation of exosomes, including those based on sieving, deterministic lateral displacement, field flow, and compressive flow fractionation, as well as viscoelastic, acoustic, inertial, electrical, and centrifugal forces [9-11].

In recent years, the field of microfluidics has made it possible to develop new methods for purifying exosomes. Microfluidics provides platforms, including micron-sized channels, for processing small amounts of fluids (microliters to picoliters). Most microfluidic devices are made with a special polymer called poly dimethylsiloxane) or PDMS [3,12,13]. PDMS is optically transparent and biocompatible, making them a useful material in constructing biofluid devices. Microfluidic platforms can classify exosomes with a high degree of purity and sensitivity while reducing the cost, time, and volume of reagents. The immunoaffinity-based microfluidic technique for exosome isolation overcomes many problems of traditional ones (such as ultracentrifugation, density gradient centrifugation, tangential flow filtration, size-exclusion chromatography) because they are adjustable, automatic, scalable, and portable. Exosomes can be isolated from other components of the sample based on the same specific proteins. CD9, CD41, CD63, and CD81 as well as specific molecules like heparin, Tim4, and heat shock protein-binding peptides are common exosome surface markers for immunoaffinity-based isolation [14-17].

Herein, we have developed microfluidic devices for exosome isolation from different sources using CD68 conjugated magnetic beads [4,18,19].

2. MATERIALS AND METHODS

COMSOL simulations. The equations governing the channels were performed using COMSOL version 5.1 multiphysics software. The flow was simulated as a single-phase laminar flow and due to its thinness, the physical properties of distilled water at room temperature and pH = 7.4 were used for the simulation. The effective and optimized parameters were set as follows: The arrangement angle of the positions along the length of the chip, the designed curved channel width, the chip height, the number of mazes, the radius of curvature of the curved channel is designed, channel width at output and input, and Input flow rate.

Chip construction. Fabrication of exosome isolation microchip with the ability to load imatinib was done by standard soft lithography protocol. The silicon wafer was coated using SU8 photoresist (Microchem. Corp., Newton, MA). 5 cc of SU8 photoresist was poured on a 4-inch wafer and spin coating was done at 2300 rpm. Wafer baking after spin coat was done at 60 and 95 degrees Celsius for 2 hours and 15 minutes, respectively. After the baking was
completed, the mask was precisely aligned and exposed to UV light at 360 mV for
12 minutes on the wafer coated with SU8. After finishing the exposure, washing with
developer and isopropanol was done for 4 minutes and 8 minutes, respectively, until the
channels appeared. After preparing the mold, a 1:10 ratio of Polydimethylsiloxane
(PDMS) (Microchem. Corp., Newton, MA) and hardener was prepared and bubbled.
10 cc of PDMS and hardener solution was poured on the mold and incubated at room
temperature for 24 hours to form the PDMS chip. After the complete formation of the
PDMS gel, using plasma gas with a power of 12 mJ/min for 4 minutes, stimulation
was performed on the gel and the PDMS chip was attached to the glass (Fig. 1).

AFM microscopy. The topography, surface roughness, phase image, friction
image, magnetic properties, and thickness of the monolayer is analyzed using AFM
microscopy. To investigate the changes in chip level and post and channel heights, the
chip was washed with acetone and dried at 60°C.

Microfluidic-based exosome extraction. The three primary exosomal sources including
serum, urine, and cell culture supernatant were considered for this part of the study.
Anti-CD63 (Abcam, UK) were conjugated to Mag nanoparticles (Jiayuan Quantum
Pickup Company, Wuhan, China) using conventional methods. The total binding
capacity of the nanoparticles was estimated to be about 10 µg of CD63 antibody on 1
mg of nanoparticles when using 1 mg/mL of Mag-CD63. The sample containing the
exosome was mixed with CD63-Mag and inserted into the microfluidic chip via input
1, and the anti-CD63 (Abcam, UK) was reinserted through input 2. A dual syringe pump
with a flow rate of 1-10 μL/min flows were mixed in the first channel, resulting in the
formation of the Mag-CD63-Exo complex. Immunomagnetic particles (CD63-Mag)
were retained in chamber 1 by a magnetic disk. The PBS buffer was then introduced
from input 3 to wash the Exo-CD63-Mag complex. It was then kept in compartment
2. Immuno-conjugate exosomes were collected for examination. The isolated
exosomes from serum, urine, and cellular supernatant using a chip designed r named
as S-EXOChip, UE-EXOChip, and SU-EXOChip, respectively. Also, the input 4
gate is defined for drug loading, which will be discussed further (Fig. 2).

Exosomes protein content. Bradford method was used to determine the protein content
of the exosomes using 0.10, 0.08, 0.06, 0.04, 0.02 mg/mL of bovine serum albumin

Fig. 1. A: the steps of baking the wafer at temperatures of 60 and 95 degrees Celsius, B: the exposure process on the lined
mask on the wafer, C: the final mold after the impact of the developer and washing with isopropanol, and D the final mold of
the PDMS chip.
(BSA, Sigma, CAS no., 9048-46-8) at 595 nm [20].

Flow cytometry analysis. To evaluate the accuracy of the exosome extraction, flow cytometric analysis was performed against anti-CD63 antibody (Padza Padtenpajooh, cat#MM108, Iran) was performed on the extracted samples according to the manufacturer protocols. Briefly, 5 mg per test was added to the tubes containing exosomes, then tubes were gently mixed and incubated in the dark for 60 minutes at 2-8°C. After that, Wash the samples using 1 mL of diluted assay buffer 1X. To collect the magnetic grains, microtubes were placed in a magnetic circuit and then centrifuged at or at 3500×rpm for 10 min. Once more, 350 μL of assay buffer 1X is added to the tube and analyzed with flow cytometer (Millipore Merck Germany).

Exosome size and morphology analysis. For measuring the hydrodynamic size with DLS analysis, 200 μL of the exosomal solution of extracted cell supernatant was diluted with 420 μL of filtered PBS. The sample was then placed on ice and sonicated for 10 minutes. Finally, the sample was placed in a DLS device with 632 nm laser light beam and the results were analyzed with Zeta Sizer software.

Scanning electron microscopy (SEM) was used to analyze the size and morphology of the exosomes. Exosomes were coated with FEI Nova 200 Nanolab Dual-beam FIB scanning electron microscope under low energy (2.0-5.0 kV) in the Electron Microscopy Analysis Laboratory (MC2) by gold spraying or carbon by thermal evaporation. Then, 200 μL of extracted cell supernatant exosomes were poured onto the slide and dried for one hour at room temperature. The sample was then observed by electron microscopy.

Western blotting. The volume of 50 μL of lysis buffer was added to both extracted samples with a 1% Holt protease inhibitor (Thermofisher scientific, LTD, USA) and incubated for 2 min at room temperature. Then, samples were kept on ice for 10 minutes and centrifuged at 13000×rpm for 15 min at 4°C. finally, the samples were stored at –80°C for further analysis. The total volume of 20 μL of each sample was analyzed with 12% SDS polyacrylamide gel (SDWS-PAGE) is used to separate and determine the molecular weight of proteins with a voltage intensity of 80 mV. After separating the protein bands of the sample on SDS-PAGE gel, CD81 as a surface membrane-specific exosome protein was detected in cell lysate. In order to form an immunoblot cassette and load the gel and nitrocellulose paper on the blotting instrument (Biorad, USA). The transfer of protein bands was done for 90 min at a voltage of 100 mV. Afterward, the membrane was washed in the blocking buffer for 60 min at 37°C. Finally, the samples were stained with Anti-CD81 antibodies (1:4000) in TBS buffer (1x),
poured on PVDF membrane, and placed in a shaker incubator for 37 h at 37°C. Then it was washed three times with TBS buffer and each time for 10 min.

Exosomal RNA extraction and miRNA expression levels. RNA extraction was performed using Norgen’s Exosome RNA Isolation Kit (Cat# 58000) according to the manufacturer’s protocols. Initially, 300 μL of lysis buffer A and 37.5 μL of lysis buffer additive to each isolated exosome sample then, samples were mixed via vortexing for 10 seconds. After incubating the samples at room temperature for 10 min, 500 μL of 96% ethanol was added to the mixture and mixed well with Vortex for 10 seconds. Afterward, 500 μL of the mixture is transferred to the Mini Spin column and centrifuge at 6000×rpm for 1 min. After repeating the former step, 600 μL of washing solution A is added onto the column and centrifuge at 13000×rpm for 30 sec, followed by centrifuge at 13000×rpm for 1 minute. Finally, the volume of 50 μl of wash solution A is added onto the column and centrifuge at 8000×rpm for 1 min and stored at –80°C for further analysis.

The total non-coding RNAs and small RNAs such as miRNAs were converted to the cDNA extraction kit (ABM good Cat# G902). The miRNA sample was prepared by mixing 2 μL of 5X poly (A) polymerase reaction buffer, 1.5 μL ATP (10Mm), 0.5 μL Poly (A) Polymerase, Yeast (1μg/μL), and 2.5 μL of H₂O. Then, the mixture was incubated for 30 min at 37°C. Then 2 μl of miRNA Oligo (dT) adapter (10 mM) was added to the rest of the material. The mixture was incubated for 5 minutes at 65°C followed by cooling on crushed ice. Finally, 1 μL of dNTPs (10 mM), 4 μL of 5X RT buffer, 1 μl RTase (200U/ μL) and 2 μL H₂O were added to the above mixture. The cDNA synthesis was performed by incubating the samples for 15 min at 42°C and 10 min at 70°C. The microRNA content of the samples from three sources: urine, serum, and cellular supernatant was determined using the miRCURY™ LNATM microRNA Array Hy3™/Hy5™ kit (Exiqon, Denmark) following the standard protocols. Exosome isolation using Norgen Exosome Isolation Kit (Cat#58000) from three sources: urine, serum, and cellular supernatant. The qRT-PCR was performed for each sample in three Real-time PCR System by following the manufacturer’s instructions and using different primers (Table 1). The mixture of 7 μL of Exiqon PCR Mastermix, 0.5 μL of panel Primer (5 pmol/μL), 3 μL of Tailed cDNA and 3 μL of Enhancer, and 4 μL of DEPC Treated water were prepared. The relative expression of miRNA-155 has assessed the method with U6 as a housekeeping control.

Drug loading. The modified method of direct incubation of the drugs and CD63-Mag captured exosomes with a freeze-thaw cycle to increase is used for loading imatinib. The exosomes were incubated with the imatinib with different concentrations. 10 nM of imatinib with an injection flow rate of 1μL/min was transferred to the input 4 of chips, at 25°C for 20 min. Then, papain and trypsin with concentrations of 0.1 and

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mir150-5p-Forward</td>
<td>5’-TCCCAACCCCTTGACCAGTGAA-3’</td>
</tr>
<tr>
<td>Mir150-5p-Reverse</td>
<td>Universal</td>
</tr>
<tr>
<td>Mir92a-3p-Forward</td>
<td>5’-CAGTTGCGCGCGTCTGAA-3’</td>
</tr>
<tr>
<td>Mir92a-3p-Reverse</td>
<td>Universal</td>
</tr>
<tr>
<td>Mir155-5p-Forward</td>
<td>5’-TGCTAATCGTGATAGGGGTAAA-3’</td>
</tr>
<tr>
<td>Mir155-5p-Reverse</td>
<td>Universal</td>
</tr>
<tr>
<td>Mir378-Forward</td>
<td>5’-CTGGACCTGAGGCGCAAGAAA-3’</td>
</tr>
<tr>
<td>Mir378-Reverse</td>
<td>Universal</td>
</tr>
</tbody>
</table>

Table 1

The qRT-PCR primers used for cDNA synthesis
0.02% have injected into the channel with a flow rate of 1 μL/min, respectively.

**Drug release.** The imatinib release was studied using a dialysis bag. 3 μg of exosome was homogenized in 3 mL of PBS buffer and then transferred to the dialysis bag and placed in a closed container with 60 mL of PBS buffer pH=7.4 and the temperature was stabilized at 37 °C. The released imatinib content was calculated and at the wavelength of 242 nm using UV-Visible spectroscopy. The standard curve was drawn using 1, 2, 5, 10, 15, 20, and 25.30 μg/mL in PBS solution.

**Cell toxicity.** MTT assay is used to evaluate the toxicity of imatinib-loaded CD63-Mag captured exosomes against the KYO-1 cell line. The cellular metabolism of the cells was determined via monitoring the mitochondrial dehydrogenase enzymes activity using methythiazole tetrazolium bromide (MTT) as a substrate. In this regard, 10,000 cells were pre-cultured in 96 well plates were incubated for 24 h at 37°C with 4% CO₂ and 90% humidity. The exosomal samples were with different concentrations including 2, 4, 8, 10, 20, 50, 100 mg/ml were treated for 24, 48, and 72 hours. Afterward, 20 μL of MTT solution (10 mg/mL) was added to each well and incubated for 4 h in the above-mentioned condition. Finally, the supernatant was discarded and 100 μL of DMSO was added to each well, shaken for 8 minutes in a circular motion, and then the absorption of formazan at 490 nm was measured using an ELISA reader. The cell viability percentage (IC50) was examined using Graphpad Prism 6.0 software (USA).

**Statistical Analysis.** The statistical data was analyzed by Prism 7.0 (GraphPad Software, USA). The significance of RNA quantities and qRT-PCR validation of miRNAs among exosomes was evaluated with one direct T-test. The p < 0.05 was considered to be statistically significant.

### 3. RESULTS

In the present study, we used a microfluidic system for capturing CD63 conjugated magnetic beads for highly efficient exosome separation. Polydimethylsiloxane (PDMS) chip mold is made of SU-8 100 patterned silicon wafer using standard soft lithography technique with immunoaffinity function (Figs 1 and 3). Fig. 2 shows the variety of inputs, chambers, channels and output of the chip.

Images from an atomic force microscope (AFM) showed the surface of the chip. As illustrated in Fig. 4, the two-dimensional (2D) and three-dimensional (3D) images of the SU-8 100 surface. After extraction of the exosomes with CD68-Mag, the physicochemical properties of the extracted exosomes were investigated using DLS, SEM, flow cytometry, Bradford, qRT-PCR, and western blotting analysis. In this regard, exosome samples were examined by flow cytometry in the presents and...
absence of protease enzyme (Fig. 5A-D). The hydrodynamic size of the extracted exosome from various biological sources using both commercially available kit and SU-8 100 chip was evaluated. Fig. 5E showed the hydrodynamic size distribution of extracted exosomes via DLS analysis which estimated the majority population within the mean diameter of 135 nm. The SEM analysis image is shown in Fig. 5F. As it can be seen, spherical shape exosomes with a diameter between 30 and 175 nm could be detected. The Comparative study of cell supernatant and urinary derived exosome protein contents using chip and kit methods with semi-quantitative method Bradford is presented in Fig. 6. The protein content of serum and cellular supernatant were not significantly altered using both techniques. In the case of urinary extracted exosomes, although the commercially available protein content showed significantly higher, the proteins from the exosomes extracted by the chip are more homogeneous.

---

**Fig. 4.** (A) 3D and (B) 2D images of the SU-8 100 chip surface.

**Fig. 5.** (A) The Flow cytometry analysis of the sample extracted by the chip against the CD68-PE antibody. (B) The chip extracted the sample in the presence of protease enzymes. (C) Chip-extracted sample histogram (D) Chip-extracted sample histogram in presence of protease enzymes. (E) The DLS histogram of isolates exosomes. (F) The SEM images of extracted exosomes.

**Fig. 6.** The protein content of the (A) cell supernatant, (B) urinary exosomes, and (C) serum using SU-8 100 chip commercially available kit with Bradford.
Investigation of the expression profile of exosome microRNAs. After RNA extraction was performed under RNase free conditions, agarose gel electrophoresis was performed to confirm the health of RNAs and their quality. In gel examination, the presence of ribosomal S28, S18, and S5 bands indicates no RNA degradation. In addition, the smear observed between these two bands indicates the presence of mRNA (Fig. 7A). The diagram below shows the y-axis showing microRNA expression based on its reference gene, U6, and the horizontal axis showing the origin of the exosome samples extracted by the commercialized kit and chip designed in this study. According to Figs 7B to 7E and Table 2, no significant relative differences in miRNAs were observed. This indicates that the designed chip was able to isolate it without damaging the nucleic acid contents of the exosome.

The imatinib Release. Since the preservation of the drug carrier structure such as the exosome is very effective on drug release, the release of imatinib from the extracted exosomes was investigated using both imatinib-loaded CD63-Mag captured exosome with chip. Fig. 6A showed the adsorption peak taken from imatinib solution in PBS. As can be seen, imatinib maximum absorption peak is located at 242 ± 1 nm. The Calibration curve with R2 = 0.994 was
Cell toxicity assessments. The comparison study of free imatinib, imatinib-loaded CD63-Mag captured exosome with chip and commercially available kit on the survival rate of KYO-1 cell line was done. According to Figs 9A to 9C, the results indicate a dose-dependent toxicity of free imatinib, imatinib-loaded CD63-Mag captured exosome with chip and available kits on KYO-1 cells. In addition, when the cells were treated with the extracted exosome using a commercialized kit, the effective dose was changed to 100 μmol, but it is noteworthy that due to the preservation of the structure and morphology of the extracted exosome by the chip over time. The effective dose was equivalent to when imatinib was treated directly on the cells.

4. DISCUSSIONS
In the last decade, there has been a growing interest in the role of exosomes as the fluid
biopsy in the detection of cancer biomarkers. These studies have highlighted the urgent need for new technologies for the rapid and accurate separation of exosomes in body fluids with minimal sample preparation steps [21-25]. Exposure of exosomes to contamination and mechanical damage leads to serious issues in purity and more intact performance. The microfluidic-based exosome extraction improves the methods of many of the earlier techniques, in many aspects including isolation, molecular analysis, and detection. With the help of microfluidic technology, high-capacity exosome analyzes of up to 100 μL/min have been obtained with detection limits of about 50 exosomes/μL [3,26,27].

With the development of exosome research, it is recognized that exosomes are closely related to many physiological activities and the emergence and development of diseases. Therefore, exosome isolation and analysis are very important for exosome-related research and applications [14, 28-30]. However, traditional exosome isolation methods have many limitations, such as expensive instruments and reagents and significant time consumption. Compared with traditional methods, microfluidic technology has the advantages of high efficiency and high sensitivity in exosome separation. In recent years, with the rapid development of technology and more research, microfluidic technology has enabled the efficient separation, enrichment, and detection of multiple information of exosomes integrated into a single chip. This indicates that microfluidic chips have great potential in clinical research such as point-of-care testing [6,13,14,17,28-30].

Similar to this study has been conducted using anti-CD9 immuno-affinity magnetic beads using streptavidin–biotin conjugates on plasma samples with high separation efficiency and increased sensitivity. Also, bead-based protocols do not impose a limit on the sample size. In another study, anti-CD9 conjugated, anti-CD81, and antibody cocktail-conjugated magnetic nanowires magnetic beads were used for immunoaffinity isolation which provided approximately threefold greater yield than conventional methods. Also, Tim4 which binds specifically to the phosphatidylserine located on exosome cell surface, showed lower contamination than those obtained using conventional methods [31-33].

Microfluidic devices have been introduced to improve detection and isolation methods by facilitating the immunological separation, screening, and capture of exosomes. This makes them very attractive targets for disease detection and analysis. As a number of studies have shown, specific proteins and nucleic acids, the "cargo" of exosomes, can be an important source of biomarkers obtained from biofluids [34-37]. RNA analysis of exosomes from liquid biopsy samples could complement information from classical DNA analysis, clarifying specific processes and eventually paving the way for personalized medicine. Considering such aspects, liquid biopsy using microfluidic systems may also emerge as an important strategy in the development of personalized targeted therapy and disease monitoring [38]. The main scope of research into microfluidic devices will be how to overcome the challenges encountered on the path towards clinical translation and clinical application of exosomes as biomarker sources [39]. Various emerging microfluidic LOC platforms seek to increase the sensitivity of the isolation process and further facilitate in situ analysis. This is in line with the current trend and demand.
for the realization of 'smart' systems with increased functionality and ease of use even by non-specialists in POCT [23]. Moreover, the realization, standardization and use of such advanced equipment could be the first step towards personalized healthcare. It may also bring closer the more distant goal of realizing a machine for the holistic separation and analysis of all liquid biopsy components to enable highly effective predictive medicine for truly personalized diagnosis and treatment [23]. To pave the way for such equipment to become widely accepted by medical practitioners worldwide, the complexity and difficulty of clinical trials and validation will also need to be overcome. Moreover, the ultimate challenge in the clinic is to perfect the technology, increase the dynamic range of the platforms, and produce cost-effective, specific, and sensitive devices for personalized medicine [4,8,17].

Particularly, immunoaffinity-based particle trapping is a highly specific way for exosome separation that can be integrated into microfluidic platforms. Several studies have conducted the use of antibody-conjugated magnetic beads for exosome separation. The CD9 conjugated magnetic beads in different sizes were tested for plasma exosome separation using an external force for magnetic beads movements with 10-15 times higher efficiencies than ultracentrifuges [27]. They have found that incubation of antibodies conjugated magnetic beads with solutions containing exosomes provided better conditions for the interaction between vesicles and ligands on the beads. In addition, bead-based protocols do not impose a limit on the sample size. Also, the microfluidic device based on immunoaffinity chromatography (CD63) was used for plasma exosomes from pancreatic cancer patients. The separation relies on receptors with additional input for adding lysis buffer for direct extraction of RNA and protein from the exosomes. Another approach for designing a microfluidic device was conducted using an input channel to label the exosomes with fluorescent dye to quantify the exosome on the chip. In this study, a microfluidic device was introduced as a platform for separating exosomes on the chip and a fluorescent assay for rapid quantification of exosomes. Other microfluidics containing photo-lithography techniques based on micro-dimensional sites of graphene oxide (GO)/polydopamine (PDA) coated with protein G were investigated for ovarian cancer exosome separation. The designed system has potential to use the exosomes for diagnostic, and prognosis [27].

Chemotherapeutics can reduce tumor volume or cause short-term remission. However, cancer cells became resistant to chemotherapy over time. Drug resistance remains a barrier to achieving cure in patients with cancer. MSC-derived exosomes can be modified and applied in cancer therapy and promoting the chemosensitivity of cancer cells. For example, miR-302a from hucMSC exosomes suppressed cancer cell growth and migration. In another study, hucMSC-derived exosomes sensitized K562 cells to IM. Here, downregulation of miR-146a-5p in patients with CML, especially in patients with IM resistance, suggests an additional role in the acquisition of IM resistance. CML is a myeloid neoplasm caused by the BCR-ABL fusion gene, which causes dysregulated cellular proliferation and resistance to apoptosis through interference with downstream signaling pathways. It has recently been reported that miR-150 levels negatively correlate with BCR-ABL transcript
level and are significantly upregulated following reduction of BCR-ABL tyrosine kinase activity. The expression levels of miR-31, miR-155, and miR-564 were also reduced in CML and affected by BCR-ABL activity [7,40-42].

5. CONCLUSION
In summary, we developed a simple immunoaffinity-based microfluidic approach to for exosome separation by drug loading capacity. The designed system was capable to isolate exosome with high sensitivity, high recovery rate, and purity as well as low volume required and high-speed extraction procedure. The chip is scalable for the high-throughput isolation of exosomes with drug loading capacity for clinical uses. Hence, this platform should provide a useful tool in clinical applications for personalized medicine and as personal diagnostic devices in the future.

REFERENCES


24. Taverna S, Amodeo V, Saieva L, Russo A, Giallombardo M, De Leo G, Alessandro R. Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and


